TIDMAGL
Angle PLC
04 May 2020
For immediate release 4 May 2020
ANGLE plc ("the Company")
LEADING CANCER CENTRE PUBLISHES PARSORTIX WORKFLOW ADDRESSING
PROBLEMS WITH ALTERNATIVE APPROACHES
Workflow for RNA gene expression demonstrated in prostate
cancer
Researchers show that "previously undetectable prostate specific
transcripts become readily measurable"
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is pleased to announce that the University of Southern
California has published results of new work undertaken in advanced
prostate cancer demonstrating a workflow developed using ANGLE's
Parsortix(R) system to provide rapid circulating tumor cell (CTC)
enrichment and transcriptomic profiling in prostate cancer that is
scalable in a cost effective way to large numbers of patient blood
samples.
Transcriptomic profiling is the process by which cancer cells,
in this case harvested by Parsortix from a simple blood test, are
analysed to determine their RNA gene expression to identify how the
patient's cancer is developing and evading the immune system so
that decisions can be made as to which drug treatments may be most
effective for that patient at that time. Standard tissue biopsy is
invasive and reflects only a single metastatic site at a single
point in time, whereas CTC analyses may reflect multiple metastatic
sites and are repeatable allowing the dynamic nature of the cancer
to be profiled. This approach enables personalised medicine and
addresses the major problem of identifying the right drug at the
right time as most drugs only work for a proportion of patients and
a "one size fits all" approach is limited in its effectiveness.
The researchers identified key advantages of their
Parsortix-based workflow compared to other CTC approaches, as
follows:
-- high enrichment levels (high purity of cancer cells with low
levels of contaminating white blood cells) for detection of
cancer-specific genes over background noise allowing previously
undetectable prostate specific transcripts to become readily
measurable;
-- minimal manipulation (cancer cells unchanged, alive and not damaged by the process);
-- recovered target cells free of antibodies or magnetic beads
(a common problem with antibody-based capture methods avoided by
the Parsortix cell separation technique);
-- epitope agnostic (harvests clinically-relevant mesenchymal CTCs as well as epithelial cells);
-- rapid, straight forward and robust workflow;
-- flexible downstream applications.
The research has been published as a peer-reviewed publication
in the International Journal of Cancer and may be accessed via
https://angleplc.com/library/publications/ .
Associate Professor Amir Goldkorn, M.D., Associate Director for
Translational Research
USC Norris Comprehensive Cancer Center & Keck School of
Medicine of the University of Southern California, commented:
"The publication of this work with ANGLE's Parsortix system
demonstrates a straightforward and scalable approach, which can be
used to investigate novel candidate biomarkers and therapeutic
targets in advanced disease."
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"University of Southern California's workflow using the
Parsortix system is a significant step forward as it demonstrates a
simple, effective way to utilise the harvested CTCs for gene
expression analysis to advise drug selection decisions and to
provide a dynamic analysis of the effectiveness of treatment. We
believe the applicability of the workflow will not be limited to
prostate cancer and may extend to most, if not all, solid tumor
cancer types."
For further information:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Carl Holmes, Simon
Hicks
ECM - Alice Lane, Sunila de Silva +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks, Andrew Craig,
Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with
sample-to-answer solutions. ANGLE's proven patent protected
platforms include a circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(R)
system, and it enables a liquid biopsy (a simple blood test) to be
used to provide cells of interest to users in a format suitable for
multiple types of downstream analyses. The system uses a
microfluidic device that captures cells based on a combination of
their size and compressibility. The system is epitope independent
and can capture all types of CTCs as well as CTC clusters in a
viable form (alive). CTCs enable the complete picture of a cancer
to be seen, as being a complete cell allows DNA, RNA and protein
analysis, and the live cells harvested can also be cultured. The
Parsortix technology is the subject of 24 granted patents in
Europe, the United States, China, Australia, Canada, India, Japan
and Mexico with three extensive families of patents are being
progressed worldwide. The Parsortix system has a CE Mark in Europe
for the indicated use and submission to FDA for clearance is in
process for the United States using results from two separate
clinical studies of over 250 metastatic breast cancer patients and
associated analytical studies. ANGLE is seeking to be the first
ever FDA cleared CTC harvesting system and only the third ever FDA
cleared liquid biopsy test. ANGLE has already undertaken two
separate 200 subject clinical studies under a program designed to
develop an ovarian cancer pelvic mass triage test, with the results
showing best in class accuracy (ROC-AUC) of 95.1%. The pelvic mass
triage assay has undergone further refinement and optimisation, and
is currently in the process of a 200 patient clinical verification
study.
ANGLE's technology for the multiplex evaluation of proteins and
nucleic acids of all types is called the HyCEAD(TM) Ziplex(R)
platform and is based on a patented flow through array technology.
It provides for low cost, highly multiplexed, rapid and sensitive
capture of targets from a wide variety of sample types. A
proprietary chemistry approach (the HyCEAD method) allows for the
capture and amplification of over 100 biomarkers simultaneously in
a single reaction. The HyCEAD Ziplex system is extremely sensitive
and is ideal for measuring gene expression and other markers
directly from Parsortix harvests and was used in the ovarian cancer
pelvic mass triage test to achieve best in class accuracy (ROC-AUC)
of 95.1%.
ANGLE's proprietary technologies can be combined to provide
automated, sample-to-answer results in both centralised laboratory
and point-of-use cartridge formats.
ANGLE has established formal collaborations with world-class
cancer centres and major corporates such as Abbott, Philips and
QIAGEN, and works closely with leading CTC translational research
customers. These Key Opinion Leaders (KOLs) are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. The body of evidence as to the benefits of the Parsortix
system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with
32 peer-reviewed publications and numerous publicly available
posters, available on our website.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEASSFEALEEFA
(END) Dow Jones Newswires
May 04, 2020 02:00 ET (06:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024